Tango Therapeutics, Inc. (TNGX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$22.52-1.05%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TNGX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -23.8% |
| Our one-year growth estimate | diamond | -89.5% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 65.7 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
TNGX — earnings miss
Dated 2026-08-11
of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. Nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in the filing unless specifically stated so therein.
Why it matters: Getting capital is key for operations and trials. Delays may mean financial issues.
Supportive ifThere is news of a successful capital raise or new funding sources.
Worry ifNo new capital raised by the next earnings report on August 4, 2026.
Why it matters: Updates on cash and losses will show how Tango is handling its finances. This is important as it moves forward with clinical programs.
Worry ifCash position stays above $1 billion while net losses go down from last quarter.
Less concerning ifCash position falls below $800 million or net losses rise a lot from last quarter.
Why it matters: Growing losses show bad cost management. This can hurt investor trust and funding.
Worry ifOperating losses reported worse than -$48.77 million in Q1.
Less concerning ifOperating losses are better or stay under -$48.77 million.
Why it matters: A clear plan from the new CFO may stabilize operations. This can help investors.
Supportive ifThe new CFO shares a plan to fix operating losses.
Worry ifNo strategic plan is announced or it lacks detail.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$251 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $758 loss on $10,000 · 7.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,216 loss on $10,000 · 32.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Updates on cash will show financial health and ability to fund trials. This is vital.
Watch forThey announced a successful capital raise. This raises cash to over $380 million.
Also watch forCash position below $380 million or failure to raise more capital.
Why it matters: Starting the Phase 3 trial would show confidence in vopimetostat's chance for approval.
Supportive ifThe Phase 3 trial for vopimetostat in front-line pancreatic cancer is now starting.
Worry ifDelay or cancellation of the Phase 3 trial initiation.
Why it matters: The results will show if vopimetostat is effective. This is key for future funding and partnerships.
Supportive ifThe Phase 1/2 trial for vopimetostat has good results. It works with RAS(ON) inhibitors.
Worry ifNegative results from the trial or further delays in reporting.
Why it matters: Initial data on TNG456 could show its potential in glioblastoma. Positive results may enhance the pipeline's value.
Supportive ifThey released initial data for TNG456. It shows good effects in glioblastoma.
Worry ifInitial data shows TNG456 does not work well or has big safety problems.